Call SC1-BHC-17-2020 for prevention and/or early diagnosis of cancer now open!

Prevention, early diagnosis of cancer: call SC1-BHC-17-2020

What we can do, as an SME partner:

For the call SC1-BHC-17-2020, we can bring our expertise in microfluidic instrumentation and flow management to help you develop a lab-on-a-chip platform to detect biomarkers involved in cancer. Specifically, we can:

Develop a microfluidic setup to inject patient samples into your lab-on-a-chip and allow quick detection of specific cancer biomarkers on site without the need for a proper lab
Optimize the flow inside your lab on a chip
Propose a user-friendly and affordable platform for cancer diagnosis, adapted to be used by non-trained medical staff

What labs-on-chip can do for early cancer diagnosis?

The use of microfluidics as a tool for cancer prevention and diagnosis would address the following expected impacts of the call SC1-BHC-17:

Improve tailored and affordable prevention and/or early diagnosis

⇒ Microfluidic labs-on-chip are a very powerful tool for biomarker detection and, therefore, cancer diagnosis. They can be easily performed on-site, for example, in doctors’ offices, allowing early detection, even in low—and middle-income countries.

Inform health service providers, policy, and decision-makers on effectively scaling up cancer interventions at local, regional, and national levels, including affordability for users and health providers.

⇒ With a lab-on-a-chip, cancer diagnosis can be performed in a compact device in only a few minutes: it becomes easily accessible, stays affordable since the laboratory costs do not exist, and can be implemented on a large scale.

Reduce health inequalities and inequities, including due consideration of socio-economic, gender, and age issues where relevant, in the prevention and/or early diagnosis of cancer at both local and global levels

⇒ With lab-on-chip, there is no need to send a sample to a laboratory for long and costly analysis: obtaining a result in a few minutes on-site is possible. This technology can thus be accessible in any country, reducing the inequalities caused by poor access to medical facilities.